Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285

Int J Cardiol. 2013 Oct 3;168(3):3057-8. doi: 10.1016/j.ijcard.2013.04.097. Epub 2013 May 3.
No abstract available

Keywords: Blood pressure; CYP2C19 polymorphism; Calcium-channel blockers; Clopidogrel; Synergy.

Publication types

  • Letter
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angina, Unstable / drug therapy
  • Aryl Hydrocarbon Hydroxylases / physiology*
  • Blood Pressure / drug effects*
  • Calcium Channel Blockers / pharmacology*
  • Calcium Channel Blockers / therapeutic use
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Drug Synergism
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacology
  • Ticlopidine / therapeutic use

Substances

  • Calcium Channel Blockers
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine